You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2024

Investigational Drug Information for NNZ-2591


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug NNZ-2591?

NNZ-2591 is an investigational drug.

There have been 5 clinical trials for NNZ-2591. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2021.

The most common disease conditions in clinical trials are Syndrome, Chromosome Disorders, and Chromosome Deletion. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited and [disabled in preview].

There are seven US patents protecting this investigational drug and thirty-five international patents.

Recent Clinical Trials for NNZ-2591
TitleSponsorPhase
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)Neuren Pharmaceuticals LimitedPhase 2
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman SyndromeNeuren Pharmaceuticals LimitedPhase 2
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)Neuren Pharmaceuticals LimitedPhase 2

See all NNZ-2591 clinical trials

Clinical Trial Summary for NNZ-2591

Top disease conditions for NNZ-2591
Top clinical trial sponsors for NNZ-2591

See all NNZ-2591 clinical trials

US Patents for NNZ-2591

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NNZ-2591 ⤷  Sign Up Cyclic G-2Allylproline in treatment of Parkinson's disease Neuren Pharmaceuticals, Ltd. (Auckland, NZ) ⤷  Sign Up
NNZ-2591 ⤷  Sign Up Neuroprotective bicyclic compounds and methods for their use Neuren Pharmaceuticals Limited (Auckland, NZ) ⤷  Sign Up
NNZ-2591 ⤷  Sign Up Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy ⤷  Sign Up
NNZ-2591 ⤷  Sign Up Osmotic device containing amantadine and an osmotic salt Osmotica Kereskedelmi es Szolgaltato KFT (Budapest, HU) ⤷  Sign Up
NNZ-2591 ⤷  Sign Up Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals Neuren Pharmaceuticals Limited (Auckland, NZ) ⤷  Sign Up
NNZ-2591 ⤷  Sign Up Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals NEUREN PHARMACEUTICALS, LTD. (Auckland, NZ) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NNZ-2591

Drugname Country Document Number Estimated Expiration Related US Patent
NNZ-2591 Cyprus CY1117211 2023-09-03 ⤷  Sign Up
NNZ-2591 Denmark DK1664050 2023-09-03 ⤷  Sign Up
NNZ-2591 European Patent Office EP1664050 2023-09-03 ⤷  Sign Up
NNZ-2591 Spain ES2564803 2023-09-03 ⤷  Sign Up
NNZ-2591 Hungary HUE028528 2023-09-03 ⤷  Sign Up
NNZ-2591 Japan JP2007504235 2023-09-03 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.